New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.

Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. 4th edn. Lyon, France: International Agency for Research on Cancer; 2016.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23:313–26.e315.

pubmed: 29617669 pmcid: 6075733 doi: 10.1016/j.celrep.2018.03.075

Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d’Enghien C, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013;92:974–80.

pubmed: 23684012 pmcid: 3675229 doi: 10.1016/j.ajhg.2013.04.012

Shuch B, Ricketts CJ, Vocke CD, Komiya T, Middelton LA, Kauffman EC, et al. Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol. 2013;190:1990–8.

pubmed: 23764071 pmcid: 4193347 doi: 10.1016/j.juro.2013.06.012

Przybycin CG, Magi-Galluzzi C, McKenney JK. Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens. Adv Anat Pathol. 2013;20:245–63.

pubmed: 23752087 doi: 10.1097/PAP.0b013e318299b7c6

Williamson SR, Kum JB, Goheen MP, Cheng L, Grignon DJ, Idrees MT. Clear cell renal cell carcinoma with a syncytial-type multinucleated giant tumor cell component: implications for differential diagnosis. Hum Pathol. 2014;45:735–44.

pubmed: 24499686 doi: 10.1016/j.humpath.2013.10.033

Alaghehbandan R, Ulamec M, Martinek P, Pivovarcikova K, Michalova K, Skenderi F, et al. Papillary pattern in clear cell renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 23 cases. Ann Diagn Pathol. 2019;38:80–6.

pubmed: 30502717 doi: 10.1016/j.anndiagpath.2018.11.004

Verine J, Colin D, Nheb M, Prapotnich D, Ploussard G, Cathelineau X, et al. Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems. Am J Surg Pathol. 2018;42:423–41.

pubmed: 29356723 doi: 10.1097/PAS.0000000000001025

Lopez JI, Erramuzpe A, Guarch R, Cortes JM, Pulido R, Llarena R, et al. CD34 immunostaining enhances a distinct pattern of intratumor angiogenesis with prognostic implications in clear cell renal cell carcinoma. APMIS. 2017;125:128–33.

pubmed: 28120493 doi: 10.1111/apm.12649

Cai Q, Christie A, Rajaram S, Zhou Q, Araj E, Chintalapati S, et al. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type. EBioMed. 2020;51:102526.

doi: 10.1016/j.ebiom.2019.10.052

Singla N, Xie Z, Zhang Z, Gao M, Yousuf Q, Onabolu O, et al. Pancreatic tropism of metastatic renal cell carcinoma. JCI Insight. 2020;5:e134564.

McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, et al. Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features. J Clin Oncol. 2020;38:63–70.

pubmed: 31721643 doi: 10.1200/JCO.19.01882

Al-Ahmadie HA, Alden D, Fine SW, Gopalan A, Touijer KA, Russo P, et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol. 2011;35:949–61.

pubmed: 21677535 doi: 10.1097/PAS.0b013e31821e25cd

Donato DP, Johnson MT, Yang XJ, Zynger DL. Expression of carbonic anhydrase IX in genitourinary and adrenal tumours. Histopathology. 2011;59:1229–39.

pubmed: 22175902 doi: 10.1111/j.1365-2559.2011.04074.x

Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010;134:873–9.

pubmed: 21088149 doi: 10.1309/AJCPPPR57HNJMSLZ

Baniak N, Flood TA, Buchanan M, Dal Cin P, Hirsch MS. Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes. Histopathology. 2020;77:659–66.

pubmed: 32639054 doi: 10.1111/his.14204

Williamson SR, Gupta NS, Eble JN, Rogers CG, Michalowski S, Zhang S, et al. Clear cell renal cell carcinoma with borderline features of clear cell papillary renal cell carcinoma: combined morphologic, immunohistochemical, and cytogenetic analysis. Am J Surg Pathol. 2015;39:1502–10.

pubmed: 26457355 doi: 10.1097/PAS.0000000000000514

Dhakal HP, McKenney JK, Khor LY, Reynolds JP, Magi-Galluzzi C, Przybycin CG. Renal neoplasms with overlapping features of clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma: a clinicopathologic study of 37 cases from a single institution. Am J Surg Pathol. 2016;40:141–54.

pubmed: 26752401 doi: 10.1097/PAS.0000000000000583

Gonzalez ML, Alaghehbandan R, Pivovarcikova K, Michalova K, Rogala J, Martinek P, et al. Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells. Histopathology. 2019;74:608–17.

pubmed: 30444288 doi: 10.1111/his.13791

Williamson SR, Gill AJ, Argani P, Chen YB, Egevad L, Kristiansen G, et al. Report from the international society of urological pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer. Am J Surg Pathol. 2020;44:e47–e65.

pubmed: 32251007 pmcid: 7289677 doi: 10.1097/PAS.0000000000001476

Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 2014;32:1968–76.

pubmed: 24821879 pmcid: 4050206 doi: 10.1200/JCO.2012.45.2003

Favazza L, Chitale DA, Barod R, Rogers CG, Kalyana-Sundaram S, Palanisamy N, et al. Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database. Mod Pathol. 2017;30:1603–12.

pubmed: 28731045 doi: 10.1038/modpathol.2017.72

Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O’Brien T, et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell. 2018;173:611–23.e617.

pubmed: 29656891 pmcid: 5927631 doi: 10.1016/j.cell.2018.02.020

Cancer Genome Atlas Research, N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9.

doi: 10.1038/nature12222

Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol. 2013;63:848–54.

pubmed: 23036577 doi: 10.1016/j.eururo.2012.09.005

Pena-Llopis S, Christie A, Xie XJ, Brugarolas J. Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res. 2013;73:4173–9.

pubmed: 23832661 pmcid: 4051157 doi: 10.1158/0008-5472.CAN-13-0360

Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44:751–9.

pubmed: 22683710 pmcid: 3788680 doi: 10.1038/ng.2323

Kapur P, Pena-Llopis S, Christie A, Zhrebker L, Pavia-Jimenez A, Rathmell WK, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013;14:159–67.

pubmed: 23333114 pmcid: 4674067 doi: 10.1016/S1470-2045(12)70584-3

Gu YF, Cohn S, Christie A, McKenzie T, Wolff N, Do QN, et al. Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inactivation drive tumor grade. Cancer Disco. 2017;7:900–17.

doi: 10.1158/2159-8290.CD-17-0292

Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, et al. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Rev Mol Diagn. 2015;15:1201–10.

pubmed: 26166446 doi: 10.1586/14737159.2015.1068122

Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, et al. Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J Urol. 2016;195:180–7.

pubmed: 26300218 doi: 10.1016/j.juro.2015.07.113

Kapur P, Christie A, Raman JD, Then MT, Nuhn P, Buchner A, et al. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J Urol. 2014;191:603–10.

pubmed: 24076305 doi: 10.1016/j.juro.2013.09.041

Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell. 2018;173:581–94.e512.

pubmed: 29656895 pmcid: 5938365 doi: 10.1016/j.cell.2018.03.057

Lopez JI, Cortes JM. Multisite tumor sampling: a new tumor selection method to enhance intratumor heterogeneity detection. Hum Pathol. 2017;64:1–6.

pubmed: 28237785 doi: 10.1016/j.humpath.2017.02.010

Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183:1309–15.

pubmed: 20171681 doi: 10.1016/j.juro.2009.12.035

Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490–504.

pubmed: 24025520 doi: 10.1097/PAS.0b013e318299f0fb

Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395–400.

pubmed: 12441925 doi: 10.1016/S0022-5347(05)64153-5

Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, et al. Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol. 2013;37:1505–17.

pubmed: 24025521 doi: 10.1097/PAS.0b013e31829a85d0

Gokden N, Nappi O, Swanson PE, Pfeifer JD, Vollmer RT, Wick MR, et al. Renal cell carcinoma with rhabdoid features. Am J Surg Pathol. 2000;24:1329–38.

pubmed: 11023094 doi: 10.1097/00000478-200010000-00002

Zhang BY, Cheville JC, Thompson RH, Lohse CM, Boorjian SA, Leibovich BC, et al. Impact of rhabdoid differentiation on prognosis for patients with grade 4 renal cell carcinoma. Eur Urol. 2015;68:5–7.

pubmed: 25638439 doi: 10.1016/j.eururo.2015.01.002

Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435–41.

pubmed: 15087662 doi: 10.1097/00000478-200404000-00002

Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005;104:511–20.

pubmed: 15973740 doi: 10.1002/cncr.21206

Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612–24.

pubmed: 12717246 doi: 10.1097/00000478-200305000-00005

Przybycin CG, McKenney JK, Reynolds JP, Campbell S, Zhou M, Karafa MT, et al. Rhabdoid differentiation is associated with aggressive behavior in renal cell carcinoma: a clinicopathologic analysis of 76 cases with clinical follow-up. Am J Surg Pathol. 2014;38:1260–5.

pubmed: 25127094 doi: 10.1097/PAS.0000000000000251

Taneja K, Arora S, Rogers CG, Gupta NS, Williamson SR. Pathologic staging of renal cell carcinoma: a review of 300 consecutive cases with emphasis on retrograde venous invasion. Histopathology. 2018;73:681–91.

pubmed: 29897139 doi: 10.1111/his.13672

Bonsib SM, Bhalodia A. Retrograde venous invasion in renal cell carcinoma: a complication of sinus vein and main renal vein invasion. Mod Pathol. 2011;24:1578–85.

pubmed: 21822202 doi: 10.1038/modpathol.2011.124

Williamson SR, Taneja K, Cheng L. Renal cell carcinoma staging: pitfalls, challenges, and updates. Histopathology. 2019;74:18–30.

pubmed: 30565307 doi: 10.1111/his.13743

Bonsib SM. T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas. J Urol. 2005;174:1199–202. discussion 1202.

pubmed: 16145369 doi: 10.1097/01.ju.0000173631.01329.1f

Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590–5.

pubmed: 11431713 doi: 10.1053/hupa.2001.24984

Saleeb RM, Plant P, Tawedrous E, Krizova A, Brimo F, Evans AJ, et al. Integrated phenotypic/genotypic analysis of papillary renal cell carcinoma subtypes: identification of prognostic markers, cancer-related pathways, and implications for therapy. Eur Urol Focus. 2018;4:740–8.

pubmed: 28753789 doi: 10.1016/j.euf.2016.09.002

Saleeb RM, Brimo F, Farag M, Rompre-Brodeur A, Rotondo F, Beharry V, et al. Toward biological subtyping of papillary renal cell carcinoma with clinical implications through histologic, immunohistochemical, and molecular analysis. Am J Surg Pathol. 2017;41:1618–29.

pubmed: 28984673 doi: 10.1097/PAS.0000000000000962

Chevarie-Davis M, Riazalhosseini Y, Arseneault M, Aprikian A, Kassouf W, Tanguay S, et al. The morphologic and immunohistochemical spectrum of papillary renal cell carcinoma: study including 132 cases with pure type 1 and type 2 morphology as well as tumors with overlapping features. Am J Surg Pathol. 2014;38:887–94.

pubmed: 24919183 doi: 10.1097/PAS.0000000000000247

Yang C, Shuch B, Kluger H, Humphrey PA, Adeniran AJ. High WHO/ISUP grade and unfavorable architecture, rather than typing of papillary renal cell carcinoma, may be associated with worse prognosis. Am J Surg Pathol. 2020;44:582–93.

pubmed: 32101890 doi: 10.1097/PAS.0000000000001455

Cancer Genome Atlas Research N, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl J Med. 2016;374:135–45.

doi: 10.1056/NEJMoa1505917

Marsaud A, Dadone B, Ambrosetti D, Baudoin C, Chamorey E, Rouleau E, et al. Dismantling papillary renal cell carcinoma classification: the heterogeneity of genetic profiles suggests several independent diseases. Genes Chromosomes Cancer. 2015;54:369–82.

pubmed: 25820192 doi: 10.1002/gcc.22248

Pitra T, Pivovarcikova K, Alaghehbandan R, Hes O. Chromosomal numerical aberration pattern in papillary renal cell carcinoma: Review article. Ann Diagn Pathol. 2019;40:189–99.

pubmed: 29454759 doi: 10.1016/j.anndiagpath.2017.11.004

Hes O, Condom Mundo E, Peckova K, Lopez JI, Martinek P, Vanecek T, et al. Biphasic squamoid alveolar renal cell carcinoma: a distinctive subtype of papillary renal cell carcinoma? Am J Surg Pathol. 2016;40:664–75.

pubmed: 26999503 doi: 10.1097/PAS.0000000000000639

Trpkov K, Athanazio D, Magi-Galluzzi C, Yilmaz H, Clouston D, Agaimy A, et al. Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases. Histopathology. 2018;72:777–85.

pubmed: 29119638 doi: 10.1111/his.13432

Trpkov K, Hes O. New and emerging renal entities: a perspective post-WHO 2016 classification. Histopathology. 2019;74:31–59.

pubmed: 30565301 doi: 10.1111/his.13727

Denize T, Just PA, Sibony M, Blons H, Timsit MO, Drossart T, et al. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features. Mod Pathol. 2020. https://doi.org/10.1038/s41379-020-0645-6 .

Skenderi F, Ulamec M, Vanecek T, Martinek P, Alaghehbandan R, Foix MP, et al. Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases. Ann Diagn Pathol. 2017;27:48–56.

pubmed: 28325361 doi: 10.1016/j.anndiagpath.2017.01.005

Ulamec M, Skenderi F, Trpkov K, Kruslin B, Vranic S, Bulimbasic S, et al. Solid papillary renal cell carcinoma: clinicopathologic, morphologic, and immunohistochemical analysis of 10 cases and review of the literature. Ann Diagn Pathol. 2016;23:51–7.

pubmed: 27209513 doi: 10.1016/j.anndiagpath.2016.04.008

Al-Obaidy KI, Eble JN, Cheng L, Williamson SR, Sakr WA, Gupta N, et al. Papillary renal neoplasm with reverse polarity: a morphologic, immunohistochemical, and molecular study. Am J Surg Pathol. 2019;43:1099–111.

pubmed: 31135486 doi: 10.1097/PAS.0000000000001288

Al-Obaidy KI, Eble JN, Nassiri M, Cheng L, Eldomery MK, Williamson SR, et al. Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Mod Pathol. 2020;33:1157–64.

pubmed: 31534204 doi: 10.1038/s41379-019-0362-1

Kunju LP, Wojno K, Wolf JS Jr., Cheng L, Shah RB. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol. 2008;39:96–101.

pubmed: 17949780 doi: 10.1016/j.humpath.2007.05.016

Kim SS, Cho YM, Kim GH, Kee KH, Kim HS, Kim KM, et al. Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity-a comparative study with papillary renal cell carcinoma. Mod Pathol. 2020;33:690–9.

pubmed: 31953522 doi: 10.1038/s41379-019-0420-8

Zhou L, Xu J, Wang S, Yang X, Li C, Zhou J, et al. Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 7 Cases. Int J Surg Pathol. 2020;28:728–34.

pubmed: 32403965 doi: 10.1177/1066896920918289

Tong K, Zhu W, Fu H, Cao F, Wang S, Zhou W, et al. Frequent KRAS mutations in oncocytic papillary renal neoplasm with inverted nuclei. Histopathology. 2020;76:1070–83.

pubmed: 31997427 doi: 10.1111/his.14084

Ged Y, Chen YB, Knezevic A, Casuscelli J, Redzematovic A, DiNatale RG, et al. Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes. Clin Genitourin Cancer. 2019;17:e678–e688.

pubmed: 31036466 pmcid: 6752712 doi: 10.1016/j.clgc.2019.03.018

Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014;26:319–30.

pubmed: 25155756 pmcid: 4160352 doi: 10.1016/j.ccr.2014.07.014

Skala SL, Wang X, Zhang Y, Mannan R, Wang L, Narayanan SP, et al. Next-generation RNA sequencing-based biomarker characterization of chromophobe renal cell carcinoma and related oncocytic neoplasms. Eur Urol. 2020;78:63–74.

pubmed: 32299640 pmcid: 8996310 doi: 10.1016/j.eururo.2020.03.003

Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E, et al. Multilevel genomics-based taxonomy of renal cell carcinoma. Cell Rep. 2016;14:2476–89.

pubmed: 26947078 pmcid: 4794376 doi: 10.1016/j.celrep.2016.02.024

Drevik J, Abbosh P. Novel biomarkers in chromophobe renal cell carcinoma: distinguishing it from its mimics. Eur Urol. 2020;78:75–6.

pubmed: 32327265 doi: 10.1016/j.eururo.2020.03.045

Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol. 2008;32:1822–34.

pubmed: 18813125 doi: 10.1097/PAS.0b013e3181831e68

Przybycin CG, Cronin AM, Darvishian F, Gopalan A, Al-Ahmadie HA, Fine SW, et al. Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. Am J Surg Pathol. 2011;35:962–70.

pubmed: 21602658 doi: 10.1097/PAS.0b013e31821a455d

Delahunt B, McKenney JK, Lohse CM, Leibovich BC, Thompson RH, Boorjian SA, et al. A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am J Surg Pathol. 2013;37:311–22.

pubmed: 23348209 doi: 10.1097/PAS.0b013e318270f71c

Kovacs G, Soudah B, Hoene E. Binucleated cells in a human renal cell carcinoma with 34 chromosomes. Cancer Genet Cytogenet. 1988;31:211–5.

pubmed: 3349439 doi: 10.1016/0165-4608(88)90219-1

Tan MH, Wong CF, Tan HL, Yang XJ, Ditlev J, Matsuda D, et al. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer. 2010;10:196.

pubmed: 20462447 pmcid: 2883967 doi: 10.1186/1471-2407-10-196

Speicher MR, Schoell B, du Manoir S, Schrock E, Ried T, Cremer T, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994;145:356–64.

pubmed: 7519827 pmcid: 1887405

Brunelli M, Eble JN, Zhang S, Martignoni G, Delahunt B, Cheng L. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol. 2005;18:161–9.

pubmed: 15467713 doi: 10.1038/modpathol.3800286

Brunelli M, Gobbo S, Cossu-Rocca P, Cheng L, Hes O, Delahunt B, et al. Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma. Mod Pathol. 2007;20:303–9.

pubmed: 17277768 doi: 10.1038/modpathol.3800739

Alaghehbandan R, Trpkov K, Tretiakova M, Pires-Luis A, Rogala J. Comprehensive review of numerical chromosomal aberrations in chromophobe renal cell carcinoma including its variant morphologies. Adv Anat Pathol. 2020;28:8–20.

Ohashi R, Schraml P, Angori S, Batavia AA, Rupp NJ, Ohe C, et al. Classic chromophobe renal cell carcinoma incur a larger number of chromosomal losses than seen in the eosinophilic subtype. Cancers (Basel). 2019;11:1492.

doi: 10.3390/cancers11101492

Durinck S, Stawiski EW, Pavia-Jimenez A, Modrusan Z, Kapur P, Jaiswal BS, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet. 2015;47:13–21.

pubmed: 25401301 doi: 10.1038/ng.3146

Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, et al. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight. 2017;2:e92688.

Roldan-Romero JM, Santos M, Lanillos J, Caleiras E, Anguera G, Maroto P, et al. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. Mod Pathol. 2020;33:2580–90.

Paner G, Amin M, Moch H, Storkel S. Chromophobe renal cell carcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016. pp. 27–8.

Trpkov K, Williamson SR, Gao Y, Martinek P, Cheng L, Sangoi AR, et al. Low-grade oncocytic tumor of kidney (CD117 Negative, Cytokeratin 7 Positive): a distinct entity? Histopathology. 2019. https://doi.org/10.1111/his.13865 .

Liu YJ, Ussakli C, Antic T, Liu Y, Wu Y, True L, et al. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling. Hum Pathol. 2020;104:18–29.

pubmed: 32673684 doi: 10.1016/j.humpath.2020.07.003

Guo J, Tretiakova MS, Troxell ML, Osunkoya AO, Fadare O, Sangoi AR, et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol. 2014;38:1457–67.

pubmed: 25093518 doi: 10.1097/PAS.0000000000000248

Tjota M, Chen H, Parilla M, Wanjari P, Segal J, Antic T. Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study. Am J Surg Pathol. 2020;44:943–54.

pubmed: 32091432 doi: 10.1097/PAS.0000000000001457

Tong K, Hu Z. FOXI1 expression in chromophobe renal cell carcinoma and renal oncocytoma: a study of The Cancer Genome Atlas transcriptome-based outlier mining and immunohistochemistry. Virchows Arch. 2020. https://doi.org/10.1007/s00428-020-02900-x .

Amin MB, Crotty TB, Tickoo SK, Farrow GM. Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases. Am J Surg Pathol. 1997;21:1–12.

pubmed: 8990136 doi: 10.1097/00000478-199701000-00001

Trpkov K, Yilmaz A, Uzer D, Dishongh KM, Quick CM, Bismar TA, et al. Renal oncocytoma revisited: a clinicopathological study of 109 cases with emphasis on problematic diagnostic features. Histopathology. 2010;57:893–906.

pubmed: 21166703 doi: 10.1111/j.1365-2559.2010.03726.x

Hes O, Moch H, Reuter V. Oncocytoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016. pp. 43–4.

Wobker SE, Przybycin CG, Sircar K, Epstein JI. Renal oncocytoma with vascular invasion: a series of 22 cases. Hum Pathol. 2016;58:1–6.

pubmed: 27498062 doi: 10.1016/j.humpath.2016.07.020

Perez-Ordonez B, Hamed G, Campbell S, Erlandson RA, Russo P, Gaudin PB, et al. Renal oncocytoma: a clinicopathologic study of 70 cases. Am J Surg Pathol. 1997;21:871–83.

pubmed: 9255250 doi: 10.1097/00000478-199708000-00001

Tickoo SK, Reuter VE, Amin MB, Srigley JR, Epstein JI, Min KW, et al. Renal oncocytosis: a morphologic study of fourteen cases. Am J Surg Pathol. 1999;23:1094–101.

pubmed: 10478670 doi: 10.1097/00000478-199909000-00013

Weirich G, Glenn G, Junker K, Merino M, Storkel S, Lubensky I, et al. Familial renal oncocytoma: clinicopathological study of 5 families. J Urol. 1998;160:335–40.

pubmed: 9679872 doi: 10.1016/S0022-5347(01)62888-X

Hes O, Petersson F, Kuroda N, Hora M, Michal M. Renal hybrid oncocytic/chromophobe tumors - a review. Histol Histopathol. 2013;28:1257–64.

pubmed: 23740406

Williamson SR, Gadde R, Trpkov K, Hirsch MS, Srigley JR, Reuter VE, et al. Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Hum Pathol. 2017;63:149–56.

pubmed: 28315424 doi: 10.1016/j.humpath.2017.03.004

Gobbo S, Eble JN, Grignon DJ, Martignoni G, MacLennan GT, Shah RB, et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol. 2008;32:1239–45.

pubmed: 18594469 doi: 10.1097/PAS.0b013e318164bcbb

Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Ahmadie HA, Fine SW, et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol. 2011;24:1207–20.

pubmed: 21602815 doi: 10.1038/modpathol.2011.80

Tickoo SK, dePeralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006;30:141–53.

pubmed: 16434887 doi: 10.1097/01.pas.0000185382.80844.b1

Zhou H, Zheng S, Truong LD, Ro JY, Ayala AG, Shen SS. Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma. Hum Pathol. 2014;45:59–64.

pubmed: 24182559 doi: 10.1016/j.humpath.2013.08.004

Clemmensen T, Matoso A, Graham T, Lai WS, Rais-Bahrami S, Gordetsky J. Pathologic and clinical characteristics of early onset renal cell carcinoma. Hum Pathol. 2018;74:25–31.

pubmed: 29133143 doi: 10.1016/j.humpath.2017.11.005

Wang K, Zarzour J, Rais-Bahrami S, Gordetsky J. Clear cell papillary renal cell carcinoma: new clinical and imaging characteristics. Urology. 2017;103:136–41.

pubmed: 28130179 doi: 10.1016/j.urology.2016.12.002

Morlote DM, Harada S, Batista D, Gordetsky J, Rais-Bahrami S. Clear cell papillary renal cell carcinoma: molecular profile and virtual karyotype. Hum Pathol. 2019;91:52–60.

pubmed: 31175917 doi: 10.1016/j.humpath.2019.05.011

Cox R, Vang R, Epstein JI. Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma. Am J Surg Pathol. 2014;38:713–8.

pubmed: 24441657 doi: 10.1097/PAS.0000000000000152

Rao P, Monzon F, Jonasch E, Matin SF, Tamboli P. Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome–clinicopathological features and comparative genomic analysis of 3 cases. Hum Pathol. 2014;45:1966–72.

pubmed: 25081542 doi: 10.1016/j.humpath.2014.06.004

Williamson SR, Zhang S, Eble JN, Grignon DJ, Martignoni G, Brunelli M, et al. Clear cell papillary renal cell carcinoma-like tumors in patients with von hippel-lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma. Am J Surg Pathol. 2013;37:1131–9.

pubmed: 23648463 doi: 10.1097/PAS.0b013e318282dab8

Parilla M, Alikhan M, Al-Kawaaz M, Patil S, Kadri S, Ritterhouse LL, et al. Genetic underpinnings of renal cell carcinoma with leiomyomatous stroma. Am J Surg Pathol. 2019;43:1135–44.

pubmed: 30986793 doi: 10.1097/PAS.0000000000001255

Shah RB, Stohr BA, Tu ZJ, Gao Y, Przybycin CG, Nguyen J, et al. “Renal cell carcinoma with leiomyomatous stroma” harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am J Surg Pathol. 2020;44:571–81.

pubmed: 31850909 doi: 10.1097/PAS.0000000000001422

Adam J, Couturier J, Molinie V, Vieillefond A, Sibony M. Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases. Histopathology. 2011;58:1064–71.

pubmed: 21707708 doi: 10.1111/j.1365-2559.2011.03857.x

Xu J, Reznik E, Lee HJ, Gundem G, Jonsson P, Sarungbam J, et al. Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. Elife. 2019;8;e38986.

Gupta S, Inwards CY, Van Dyke DL, Jimenez RE, Cheville JC. Defining clear cell papillary renal cell carcinoma in routine clinical practice. Histopathology. 2020;76:1093–5.

pubmed: 31989679 doi: 10.1111/his.14071

Amin MB, MacLennan GT, Gupta R, Grignon D, Paraf F, Vieillefond A, et al. Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol. 2009;33:384–92.

pubmed: 19011562 doi: 10.1097/PAS.0b013e3181872d3f

Alexiev BA, Drachenberg CB. Tubulocystic carcinoma of the kidney: a histologic, immunohistochemical, and ultrastructural study. Virchows Arch. 2013;462:575–81.

pubmed: 23525677 doi: 10.1007/s00428-013-1398-0

Comperat E, Cheville J, Rioux-Leclerc N. Tubulocystic Renal Cell Carcinoma. In Moch H, Humphrey PA, Ulbright TM, Reutter VE, editors. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th edn. Lyon, France: International Agency for Research on Cancer; 2016. p. 38.

Ulamec M, Skenderi F, Zhou M, Kruslin B, Martinek P, Grossmann P, et al. Molecular genetic alterations in renal cell carcinomas with tubulocystic pattern: tubulocystic renal cell carcinoma, tubulocystic renal cell carcinoma with heterogenous component and familial leiomyomatosis-associated renal cell carcinoma. clinicopathologic and molecular genetic analysis of 15 cases. Appl Immunohistochem Mol Morphol. 2016;24:521–30.

pubmed: 26447894 doi: 10.1097/PAI.0000000000000213

Zhou M, Yang XJ, Lopez JI, Shah RB, Hes O, Shen SS, et al. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification. Am J Surg Pathol. 2009;33:1840–9.

pubmed: 19898225 doi: 10.1097/PAS.0b013e3181be22d1

Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, et al. The International Society of Urological Pathology (ISUP) vancouver classification of renal neoplasia. Am J Surg Pathol. 2013;37:1469–89.

pubmed: 24025519 doi: 10.1097/PAS.0b013e318299f2d1

Bhullar JS, Thamboo T, Esuvaranathan K. Unique case of tubulocystic carcinoma of the kidney with sarcomatoid features: a new entity. Urology. 2011;78:1071–2.

pubmed: 21439613 doi: 10.1016/j.urology.2011.01.038

Al-Hussain TO, Cheng L, Zhang S, Epstein JI. Tubulocystic carcinoma of the kidney with poorly differentiated foci: a series of 3 cases with fluorescence in situ hybridization analysis. Hum Pathol. 2013;44:1406–11.

pubmed: 23427871 doi: 10.1016/j.humpath.2012.11.015

Zhao M, Teng X, Ru G, Zhao Z, Hu Q, Han L, et al. Tubulocystic renal cell carcinoma with poorly differentiated foci is indicative of aggressive behavior: clinicopathologic study of two cases and review of the literature. Int J Clin Exp Pathol. 2015;8:11124–31.

pubmed: 26617832 pmcid: 4637647

Derquin F, Moreau S, Dargent F, Rioux Leclercq N, les membres du reseau C. Tubulocystic renal cell carcinoma with poorly differentiated foci. Ann Pathol. 2017;37:318–20.

pubmed: 28732560 doi: 10.1016/j.annpat.2017.05.003

Tran T, Jones CL, Williamson SR, Eble JN, Grignon DJ, Zhang S, et al. Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma. Histopathology. 2016;68:850–7.

pubmed: 26310887 doi: 10.1111/his.12840

Mehra R, Smith SC, Divatia M, Amin MB. Emerging entities in renal. Neoplasia Surg Pathol Clin. 2015;8:623–56.

pubmed: 26612218 doi: 10.1016/j.path.2015.08.004

Smith SC, Trpkov K, Chen YB, Mehra R, Sirohi D, Ohe C, et al. Tubulocystic carcinoma of the kidney with poorly differentiated foci: a frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2016;40:1457–72.

pubmed: 27635946 pmcid: 5577927 doi: 10.1097/PAS.0000000000000719

Chen YB, Brannon AR, Toubaji A, Dudas ME, Won HH, Al-Ahmadie HA, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol. 2014;38:627–37.

pubmed: 24441663 pmcid: 3984629 doi: 10.1097/PAS.0000000000000163

Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, et al. Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome. Am J Surg Pathol. 2016;40:865–75.

pubmed: 26900816 doi: 10.1097/PAS.0000000000000617

Muller M, Guillaud-Bataille M, Salleron J, Genestie C, Deveaux S, Slama A, et al. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. Mod Pathol. 2018;31:974–83.

pubmed: 29410489 doi: 10.1038/s41379-018-0017-7

Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, et al. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2018;42:279–92.

pubmed: 29309300 pmcid: 8015937 doi: 10.1097/PAS.0000000000001000

Shyu I, Mirsadraei L, Wang X, Robila V, Mehra R, McHugh JB, et al. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples. Cancer Cytopathol. 2018;126:992–1002.

pubmed: 30339328 doi: 10.1002/cncy.22071

Renshaw AA, Gould EW. Fine-needle aspiration of tubulocystic renal cell carcinoma. Diagn Cytopathol. 2018;46:707–10.

pubmed: 29624918 doi: 10.1002/dc.23933

Yang XJ, Zhou M, Hes O, Shen S, Li R, Lopez J, et al. Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol. 2008;32:177–87.

pubmed: 18223319 doi: 10.1097/PAS.0b013e318150df1d

Chen N, Nie L, Gong J, Chen X, Xu M, Chen M, et al. Gains of chromosomes 7 and 17 in tubulocystic carcinoma of kidney: two cases with fluorescence in situ hybridisation analysis. J Clin Pathol. 2014;67:1006–9.

pubmed: 25015070 doi: 10.1136/jclinpath-2014-202363

Skenderi F, Ulamec M, Vranic S, Bilalovic N, Peckova K, Rotterova P, et al. Cystic renal oncocytoma and tubulocystic renal cell carcinoma: morphologic and immunohistochemical comparative study. Appl Immunohistochem Mol Morphol. 2016;24:112–9.

pubmed: 26180933 doi: 10.1097/PAI.0000000000000156

Sarungbam J, Mehra R, Tomlins SA, Smith SC, Jayakumaran G, Al-Ahmadie H, et al. Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile. Mod Pathol. 2019;32:701–9.

pubmed: 30622286 pmcid: 7549436 doi: 10.1038/s41379-018-0185-5

Lawrie CH, Armesto M, Fernandez-Mercado M, Arestin M, Manterola L, Goicoechea I, et al. Noncoding RNA expression and targeted next-generation sequencing distinguish tubulocystic renal cell carcinoma (TC-RCC) from other renal neoplasms. J Mol Diagn. 2018;20:34–45.

pubmed: 29056573 doi: 10.1016/j.jmoldx.2017.09.002

Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159:179–92.

pubmed: 11438465 pmcid: 1850400 doi: 10.1016/S0002-9440(10)61684-7

Argani P, Antonescu CR, Couturier J, Fournet JC, Sciot R, Debiec-Rychter M, et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol. 2002;26:1553–66.

pubmed: 12459622 doi: 10.1097/00000478-200212000-00003

Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31:1149–60.

pubmed: 17667536 doi: 10.1097/PAS.0b013e318031ffff

Green WM, Yonescu R, Morsberger L, Morris K, Netto GJ, Epstein JI, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013;37:1150–63.

pubmed: 23715164 doi: 10.1097/PAS.0b013e31828a69ae

Clark J, Lu YJ, Sidhar SK, Parker C, Gill S, Smedley D, et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene. 1997;15:2233–9.

pubmed: 9393982 doi: 10.1038/sj.onc.1201394

Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20:48–57.

pubmed: 11244503 doi: 10.1038/sj.onc.1204074

Argani P, Zhang L, Reuter VE, Tickoo SK, Antonescu CR. RBM10-TFE3 renal cell carcinoma: a potential diagnostic pitfall due to cryptic intrachromosomal Xp11.2 inversion resulting in false-negative TFE3 FISH. Am J Surg Pathol. 2017;41:655–62.

pubmed: 28296677 pmcid: 5391276 doi: 10.1097/PAS.0000000000000835

Xia QY, Wang XT, Zhan XM, Tan X, Chen H, Liu Y, et al. Xp11 translocation renal cell carcinomas (RCCs) with RBM10-TFE3 gene fusion demonstrating melanotic features and overlapping morphology with t(6;11) RCC: interest and diagnostic pitfall in detecting a paracentric inversion of TFE3. Am J Surg Pathol. 2017;41:663–76.

pubmed: 28288037 doi: 10.1097/PAS.0000000000000837

Argani P, Zhong M, Reuter VE, Fallon JT, Epstein JI, Netto GJ, et al. TFE3-fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers. Am J Surg Pathol. 2016;40:723–37.

pubmed: 26975036 pmcid: 4864095 doi: 10.1097/PAS.0000000000000631

Huang W, Goldfischer M, Babayeva S, Mao Y, Volyanskyy K, Dimitrova N, et al. Identification of a novel PARP14-TFE3 gene fusion from 10-year-old FFPE tissue by RNA-seq. Genes Chromosomes Cancer. 2015;54:500–5.

pubmed: 26032162 doi: 10.1002/gcc.22261

Classe M, Malouf GG, Su X, Yao H, Thompson EJ, Doss DJ, et al. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas. Histopathology. 2017;70:1089–97.

pubmed: 28106924 doi: 10.1111/his.13167

Pei J, Cooper H, Flieder DB, Talarchek JN, Al-Saleem T, Uzzo RG, et al. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma. Mod Pathol. 2019;32:710–6.

pubmed: 30622287 pmcid: 6486435 doi: 10.1038/s41379-018-0191-7

Fukuda H, Kato I, Furuya M, Tanaka R, Takagi T, Kondo T, et al. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion. Virchows Arch. 2019;474:389–93.

pubmed: 30552521 doi: 10.1007/s00428-018-2509-8

Argani P, Lui MY, Couturier J, Bouvier R, Fournet JC, Ladanyi M. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene. 2003;22:5374–8.

pubmed: 12917640 doi: 10.1038/sj.onc.1206686

Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27:750–61.

pubmed: 12766578 doi: 10.1097/00000478-200306000-00005

Zhong M, De Angelo P, Osborne L, Keane-Tarchichi M, Goldfischer M, Edelmann L, et al. Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. Am J Surg Pathol. 2010;34:757–66.

pubmed: 20421778 pmcid: 7386799 doi: 10.1097/PAS.0b013e3181dd577e

Mosquera JM, Dal Cin P, Mertz KD, Perner S, Davis IJ, Fisher DE, et al. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. Diagn Mol Pathol. 2011;20:129–37.

pubmed: 21817901 doi: 10.1097/PDM.0b013e31820e9c67

Argani P, Zhang L, Sung YS, White MJ, Miller K, Hopkins M, et al. A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor. Genes Chromosomes Cancer. 2019. https://doi.org/10.1002/gcc.22801 .

Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009;22:1016–22.

pubmed: 19396149 doi: 10.1038/modpathol.2009.58

Martignoni G, Gobbo S, Camparo P, Brunelli M, Munari E, Segala D, et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol. 2011;24:1313–9.

pubmed: 21602817 doi: 10.1038/modpathol.2011.93

Pivovarcikova K, Grossmann P, Alaghehbandan R, Sperga M, Michal M, Hes O. TFE3-fusion variant analysis defines specific clinicopathologic associations amog Xp11 translocation cancers. Am J Surg Pathol. 2017;41:138–40.

pubmed: 27631518 doi: 10.1097/PAS.0000000000000730

Song Y, Yin X, Xia Q, Zheng L, Yao J, Zeng H, et al. Xp11 translocation renal cell carcinoma with morphological features mimicking multilocular cystic renal neoplasm of low malignant potential: a series of six cases with molecular analysis. J Clin Pathol. 2020. https://doi.org/10.1136/jclinpath-2020-206681 .

Sukov WR, Hodge JC, Lohse CM, Leibovich BC, Thompson RH, Pearce KE, et al. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol. 2012;36:663–70.

pubmed: 22498819 doi: 10.1097/PAS.0b013e31824dd972

Ellis CL, Eble JN, Subhawong AP, Martignoni G, Zhong M, Ladanyi M, et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Mod Pathol. 2014;27:875–86.

pubmed: 24309327 doi: 10.1038/modpathol.2013.208

Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008;112:1607–16.

pubmed: 18278810 doi: 10.1002/cncr.23331

Marcon J, DiNatale RG, Sanchez A, Kotecha RR, Gupta S, Kuo F, et al. Comprehensive genomic analysis of translocation renal cell carcinoma reveals copy-number variations as drivers of disease progression. Clin Cancer Res. 2020;26:3629–40.

pubmed: 32220885 pmcid: 7367714 doi: 10.1158/1078-0432.CCR-19-3283

Agaram NP, Sung YS, Zhang L, Chen CL, Chen HW, Singer S, et al. Dichotomy of genetic abnormalities in PEComas with therapeutic implications. Am J Surg Pathol. 2015;39:813–25.

pubmed: 25651471 pmcid: 4431898 doi: 10.1097/PAS.0000000000000389

Rao Q, Shen Q, Xia QY, Wang ZY, Liu B, Shi SS, et al. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity. Am J Surg Pathol. 2015;39:1181–96.

pubmed: 26274027 doi: 10.1097/PAS.0000000000000502

Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34:1395–406.

pubmed: 20871214 doi: 10.1097/PAS.0b013e3181f17ac0

Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29:230–40.

pubmed: 15644781 doi: 10.1097/01.pas.0000146007.54092.37

Smith NE, Illei PB, Allaf M, Gonzalez N, Morris K, Hicks J, et al. t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 2014;38:604–14.

pubmed: 24618616 pmcid: 4370182 doi: 10.1097/PAS.0000000000000203

Argani P, Yonescu R, Morsberger L, Morris K, Netto GJ, Smith N, et al. Molecular Confirmation of t(6;11)(p21;q12) Renal Cell Carcinoma in Archival Paraffin-embedded Material Using a Break-apart TFEB FISH Assay Expands its Clinicopathologic Spectrum. Am J Surg Pathol. 2012;36:1516–26.

pubmed: 22892601 pmcid: 4441265 doi: 10.1097/PAS.0b013e3182613d8f

Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–45.

Xia QY, Wang XT, Fang R, Wang Z, Zhao M, Chen H, et al. Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs): expanding the genomic spectrum. Am J Surg Pathol. 2020;44:477–89.

pubmed: 31764220 doi: 10.1097/PAS.0000000000001408

Peckova K, Vanecek T, Martinek P, Spagnolo D, Kuroda N, Brunelli M, et al. Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature. Ann Diagn Pathol. 2014;18:351–7.

pubmed: 25438924 doi: 10.1016/j.anndiagpath.2014.10.002

Argani P, Reuter VE, Zhang L, Sung YS, Ning Y, Epstein JI, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol. 2016;40:1484–95.

pubmed: 27565001 pmcid: 5069163 doi: 10.1097/PAS.0000000000000720

Skala SL, Xiao H, Udager AM, Dhanasekaran SM, Shukla S, Zhang Y, et al. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod Pathol. 2018;31:179–97.

pubmed: 28840857 doi: 10.1038/modpathol.2017.99

Williamson SR, Grignon DJ, Cheng L, Favazza L, Gondim DD, Carskadon S, et al. Renal cell carcinoma with chromosome 6p amplification including the TFEB gene: a novel mechanism of tumor pathogenesis? Am J Surg Pathol. 2017;41:287–98.

pubmed: 28009604 doi: 10.1097/PAS.0000000000000776

Gupta S, Johnson SH, Vasmatzis G, Porath B, Rustin JG, Rao P, et al. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Mod Pathol. 2017;30:998–1012.

pubmed: 28338654 doi: 10.1038/modpathol.2017.24

Gupta S, Argani P, Jungbluth AA, Chen YB, Tickoo SK, Fine SW, et al. TFEB expression profiling in renal cell carcinomas: clinicopathologic correlations. Am J Surg Pathol. 2019;43:1445–61.

pubmed: 31600176 pmcid: 6788764 doi: 10.1097/PAS.0000000000001307

Xia QY, Wang XT, Ye SB, Wang X, Li R, Shi SS, et al. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH. Histopathology. 2018;72:786–94.

pubmed: 29148086 doi: 10.1111/his.13439

Kondo T, Sasa N, Yamada H, Takagi T, Iizuka J, Kobayashi H, et al. Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study. Pathol Int. 2018;68:543–9.

pubmed: 30187581 doi: 10.1111/pin.12718

Kojima F, Gandhi JS, Matsuzaki I, Iba A, Collier S, Yoshikawa T, et al. Comprehensive clinicopathologic analyses of acquired cystic disease-associated renal cell carcinoma with focus on adverse prognostic factors and metastatic lesions. Am J Surg Pathol. 2020;44:1031–9.

pubmed: 32271189 doi: 10.1097/PAS.0000000000001482

Shah A, Lal P, Toorens E, Palmer MB, Schwartz L, Vergara N, et al. Acquired cystic kidney disease-associated renal cell carcinoma (ACKD-RCC) harbor recurrent mutations in KMT2C and TSC2 genes. Am J Surg Pathol. 2020;44:1479–86.

Przybycin CG, Harper HL, Reynolds JP, Magi-Galluzzi C, Nguyen JK, Wu A, et al. Acquired cystic disease-associated renal cell carcinoma (ACD-RCC): a multiinstitutional study of 40 cases with clinical follow-up. Am J Surg Pathol. 2018;42:1156–65.

pubmed: 29851703 doi: 10.1097/PAS.0000000000001091

Hosseini M, Antic T, Paner GP, Chang A. Pathologic spectrum of cysts in end-stage kidneys: possible precursors to renal neoplasia. Hum Pathol. 2014;45:1406–13.

pubmed: 24775605 doi: 10.1016/j.humpath.2014.02.014

Matoso A, Chen YB, Rao V, Wang L, Cheng L, Epstein JI. Atypical renal cysts: a morphologic, immunohistochemical, and molecular study. Am J Surg Pathol. 2016;40:202–11.

pubmed: 26574846 doi: 10.1097/PAS.0000000000000557

Cheuk W, Lo ES, Chan AK, Chan JK. Atypical epithelial proliferations in acquired renal cystic disease harbor cytogenetic aberrations. Hum Pathol. 2002;33:761–5.

pubmed: 12196929 doi: 10.1053/hupa.2002.125370

Sun Y, Argani P, Tickoo SK, Epstein JI. Acquired cystic disease-associated renal cell carcinoma (ACKD-RCC)-like Cysts. Am J Surg Pathol. 2018;42:1396–401.

pubmed: 30001236 doi: 10.1097/PAS.0000000000001124

Kuroda N, Shiotsu T, Hes O, Michal M, Shuin T, Lee GH. Acquired cystic disease-associated renal cell carcinoma with gain of chromosomes 3, 7, and 16, gain of chromosome X, and loss of chromosome Y. Med Mol Morphol. 2010;43:231–4.

pubmed: 21267700 doi: 10.1007/s00795-009-0465-8

Pan CC, Chen YJ, Chang LC, Chang YH, Ho DM. Immunohistochemical and molecular genetic profiling of acquired cystic disease-associated renal cell carcinoma. Histopathology. 2009;55:145–53.

pubmed: 19694821 doi: 10.1111/j.1365-2559.2009.03361.x

Gupta R, Billis A, Shah RB, Moch H, Osunkoya AO, Jochum W, et al. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol. 2012;36:1265–78.

pubmed: 22895263 doi: 10.1097/PAS.0b013e3182635954

Singh JA, Ohe C, Smith SC. High grade infiltrative adenocarcinomas of renal cell origin: New insights into classification, morphology, and molecular pathogenesis. Pathol Int. 2018;68:265–77.

pubmed: 29665139 doi: 10.1111/pin.12667

Msaouel P, Tannir NM, Walker CL. A model linking sickle cell hemoglobinopathies and SMARCB1 loss in renal medullary carcinoma. Clin Cancer Res. 2018;24:2044–9.

pubmed: 29440190 doi: 10.1158/1078-0432.CCR-17-3296

Amin MB, Smith SC, Agaimy A, Argani P, Comperat EM, Delahunt B, et al. Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. Am J Surg Pathol. 2014;38:871–4.

pubmed: 24805860 doi: 10.1097/PAS.0000000000000222

Amin M, Merino M. Renal medullary carcinoma. In: 2016 WHO classification of tumors of hte urinary system and male genital organs. Lyon; 2016. pp. 31–2.

Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017;120:782–92.

pubmed: 27860149 doi: 10.1111/bju.13705

Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol. 2013;37:368–74.

pubmed: 23348212 pmcid: 7604824 doi: 10.1097/PAS.0b013e3182770406

Calderaro J, Moroch J, Pierron G, Pedeutour F, Grison C, Maille P, et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology. 2012;61:428–35.

pubmed: 22686875 doi: 10.1111/j.1365-2559.2012.04228.x

Agaimy A, Cheng L, Egevad L, Feyerabend B, Hes O, Keck B, et al. Rhabdoid and undifferentiated phenotype in renal cell carcinoma: analysis of 32 cases indicating a distinctive common pathway of dedifferentiation frequently associated with SWI/SNF complex deficiency. Am J Surg Pathol. 2017;41:253–62.

pubmed: 27984237 doi: 10.1097/PAS.0000000000000787

Agaimy A, Amin MB, Gill AJ, Popp B, Reis A, Berney DM, et al. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients. Hum Pathol. 2018;77:139–46.

Rao P, Tannir NM, Tamboli P. Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall. Am J Surg Pathol. 2012;36:583–8.

pubmed: 22301499 doi: 10.1097/PAS.0b013e3182417d78

Jia L, Carlo MI, Khan H, Nanjangud GJ, Rana S, Cimera R, et al. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases. Mod Pathol. 2019;32:1329–43.

pubmed: 30980040 pmcid: 6731129 doi: 10.1038/s41379-019-0273-1

Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, et al. Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma. Cancer Cell. 2020;37:720–34.

Calderaro J, Masliah-Planchon J, Richer W, Maillot L, Maille P, Mansuy L, et al. Balanced translocations disrupting SMARCB1 are hallmark recurrent genetic alterations in renal medullary carcinomas. Eur Urol. 2016;69:1055–61.

pubmed: 26433572 doi: 10.1016/j.eururo.2015.09.027

Sirohi D, Smith SC, Ohe C, Colombo P, Divatia M, Dragoescu E, et al. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma. Hum Pathol. 2017;67:134–45.

pubmed: 28716439 doi: 10.1016/j.humpath.2017.07.006

Tsuzuki S, Kataoka TR, Ito H, Ueshima C, Asai S, Yokoo H, et al. A case of renal cell carcinoma unclassified with medullary phenotype without detectable gene deletion. Pathol Int. 2019;69:710–4.

pubmed: 31617267 doi: 10.1111/pin.12858

Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, De Nictolis M, Santoni M, et al. Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. Pathology. 2014;46:653–5.

pubmed: 25393261 doi: 10.1097/PAT.0000000000000175

Lai JZ, Lai HH, Cao D. Renal cell carcinoma, unclassified with medullary phenotype and synchronous renal clear cell carcinoma present in a patient with no sickle cell trait/disease: diagnostic and therapeutic challenges. Anticancer Res. 2018;38:3757–61.

pubmed: 29848739 doi: 10.21873/anticanres.12657

Rao Q, Xia QY, Shen Q, Shi SS, Tu P, Shi QL, et al. Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC. Int J Clin Exp Pathol. 2014;7:1782–7.

pubmed: 24817979 pmcid: 4014263

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, et al. Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma. Clin Genitourin Cancer. 2019;17:1–6.

pubmed: 30287223 doi: 10.1016/j.clgc.2018.09.005

Hong AL, Tseng YY, Wala JA, Kim WJ, Kynnap BD, Doshi MB, et al. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019;8;e44161.

Wei D, Yang Y, Ricketts CJ, Vocke CD, Ball MW, Sourbier C, et al. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments. Genes Chromosomes Cancer. 2020;59:472–83.

pubmed: 32259323 pmcid: 7383978 doi: 10.1002/gcc.22847

Pal SK, Choueiri TK, Wang K, Khaira D, Karam JA, Van Allen E, et al. Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling. Eur Urol. 2016;70:516–21.

pubmed: 26149668 doi: 10.1016/j.eururo.2015.06.019

Wu AJ, Mehra R, Hafez K, Wolf JS Jr., Kunju LP. Metastases to the kidney: a clinicopathological study of 43 cases with an emphasis on deceptive features. Histopathology. 2015;66:587–97.

pubmed: 25406592 doi: 10.1111/his.12524

Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, et al. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int. 2016;117:775–82.

pubmed: 26053895 doi: 10.1111/bju.13194

Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, et al. Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study. Mod Pathol. 2018. https://doi.org/10.1038/s41379-018-0065-z .

Bertz S, Ensser A, Stoehr R, Eckstein M, Apel H, Mayr D, et al. Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas. Mod Pathol. 2020;33:1433–42.

pubmed: 32047230 doi: 10.1038/s41379-020-0489-0

Yang C, Cimera RS, Aryeequaye R, Jayakumaran G, Sarungbam J, Al-Ahmadie HA, et al. Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma. Mod Pathol. 2021;34:445–56.

Malouf GG, Comperat E, Yao H, Mouawad R, Lindner V, Rioux-Leclercq N, et al. Unique transcriptomic profile of collecting duct carcinomas relative to upper tract urothelial carcinomas and other kidney carcinomas. Sci Rep. 2016;6:30988.

pubmed: 27484008 pmcid: 4971524 doi: 10.1038/srep30988

Becker F, Junker K, Parr M, Hartmann A, Fussel S, Toma M, et al. Collecting duct carcinomas represent a unique tumor entity based on genetic alterations. PLoS ONE. 2013;8:e78137.

pubmed: 24167600 pmcid: 3805592 doi: 10.1371/journal.pone.0078137

Wang J, Papanicolau-Sengos A, Chintala S, Wei L, Liu B, Hu Q, et al. Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget. 2016;7:29901–15.

pubmed: 27144525 pmcid: 5058651 doi: 10.18632/oncotarget.9093

Chen YB, Xu J, Skanderup AJ, Dong Y, Brannon AR, Wang L, et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun. 2016;7:13131.

pubmed: 27713405 pmcid: 5059781 doi: 10.1038/ncomms13131

Rakozy C, Schmahl GE, Bogner S, Storkel S. Low-grade tubular-mucinous renal neoplasms: morphologic, immunohistochemical, and genetic features. Mod Pathol. 2002;15:1162–71.

pubmed: 12429795 doi: 10.1097/01.MP.0000031709.40712.46

Mehra R, Vats P, Cieslik M, Cao X, Su F, Shukla S, et al. Biallelic alteration and dysregulation of the hippo pathway in mucinous tubular and spindle cell carcinoma of the kidney. Cancer Disco. 2016;6:1258–66.

doi: 10.1158/2159-8290.CD-16-0267

Ren Q, Wang L, Al-Ahmadie HA, Fine SW, Gopalan A, Sirintrapun SJ, et al. Distinct genomic copy number alterations distinguish mucinous tubular and spindle cell carcinoma of the kidney from papillary renal cell carcinoma with overlapping histologic features. Am J Surg Pathol. 2018;42:767–77.

Shen SS, Ro JY, Tamboli P, Truong LD, Zhai Q, Jung SJ, et al. Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features. Ann Diagn Pathol. 2007;11:13–21.

pubmed: 17240302 doi: 10.1016/j.anndiagpath.2006.09.005

Paner GP, Srigley JR, Radhakrishnan A, Cohen C, Skinnider BF, Tickoo SK, et al. Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol. 2006;30:13–9.

pubmed: 16330937 doi: 10.1097/01.pas.0000180443.94645.50

Dhillon J, Amin MB, Selbs E, Turi GK, Paner GP, Reuter VE. Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol. 2009;33:44–9.

pubmed: 18941398 doi: 10.1097/PAS.0b013e3181829ed5

Peckova K, Martinek P, Sperga M, Montiel DP, Daum O, Rotterova P, et al. Mucinous spindle and tubular renal cell carcinoma: analysis of chromosomal aberration pattern of low-grade, high-grade, and overlapping morphologic variant with papillary renal cell carcinoma. Ann Diagn Pathol. 2015;19:226–31.

pubmed: 26009022 doi: 10.1016/j.anndiagpath.2015.04.004

Wang L, Zhang Y, Chen YB, Skala SL, Al-Ahmadie HA, Wang X, et al. VSTM2A overexpression is a sensitive and specific biomarker for mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney. Am J Surg Pathol. 2018;42:1571–84.

pubmed: 30285995 pmcid: 7903805 doi: 10.1097/PAS.0000000000001150

Pillay N, Ramdial PK, Cooper K, Batuule D. Mucinous tubular and spindle cell carcinoma with aggressive histomorphology–a sarcomatoid variant. Hum Pathol. 2008;39:966–9.

pubmed: 18400251 doi: 10.1016/j.humpath.2007.10.006

Simon RA, di Sant’agnese PA, Palapattu GS, Singer EA, Candelario GD, Huang J, et al. Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid differentiation. Int J Clin Exp Pathol. 2008;1:180–4.

pubmed: 18784804 pmcid: 2480554

Kuroda N, Hes O, Michal M, Nemcova J, Gal V, Yamaguchi T, et al. Mucinous tubular and spindle cell carcinoma with Fuhrman nuclear grade 3: a histological, immunohistochemical, ultrastructural and FISH study. Histol Histopathol. 2008;23:1517–23.

pubmed: 18830937

Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, et al. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int. 2015;116:85–92.

pubmed: 25395040 doi: 10.1111/bju.12992

Sadimin ET, Chen YB, Wang L, Argani P, Epstein JI. Chromosomal abnormalities of high grade mucinous tubular and spindle cell carcinoma of the kidney. Histopathology. 2017;71:719–24.

Ged Y, Chen YB, Knezevic A, Donoghue MTA, Carlo MI, Lee CH, et al. Mucinous tubular and spindle-cell carcinoma of the kidney: clinical features, genomic profiles, and treatment outcomes. Clin Genitourin Cancer. 2019;17:268–74.e261.

pubmed: 31151928 pmcid: 6660413 doi: 10.1016/j.clgc.2019.04.006

Adamane SA, Menon S, Prakash G, Bakshi G, Joshi A, Popat P, et al. Mucinous tubular and spindle cell carcinoma of the kidney: A case series with a brief review of the literature. Indian J Cancer. 2020;57:267–81.

Ursani NA, Robertson AR, Schieman SM, Bainbridge T, Srigley JR. Mucinous tubular and spindle cell carcinoma of kidney without sarcomatoid change showing metastases to liver and retroperitoneal lymph node. Hum Pathol. 2011;42:444–8.

pubmed: 21194728 doi: 10.1016/j.humpath.2010.07.018

Thway K, du Parcq J, Larkin JM, Fisher C, Livni N. Metastatic renal mucinous tubular and spindle cell carcinoma. Atypical behavior of a rare, morphologically bland tumor. Ann Diagn Pathol. 2012;16:407–10.

pubmed: 21684183 doi: 10.1016/j.anndiagpath.2011.04.001

Hes O, Hora M, Perez-Montiel DM, Suster S, Curik R, Sokol L, et al. Spindle and cuboidal renal cell carcinoma, a tumour having frequent association with nephrolithiasis: report of 11 cases including a case with hybrid conventional renal cell carcinoma/ spindle and cuboidal renal cell carcinoma components. Histopathology. 2002;41:549–55.

pubmed: 12460208 doi: 10.1046/j.1365-2559.2002.01515.x

Kuroda N, Naroda T, Tamura M, Taguchi T, Tominaga A, Inoue K, et al. High-grade mucinous tubular and spindle cell carcinoma: comparative genomic hybridization study. Ann Diagn Pathol. 2011;15:472–5.

pubmed: 21106420 doi: 10.1016/j.anndiagpath.2010.08.003

Arroyo MR, Green DM, Perlman EJ, Beckwith JB, Argani P. The spectrum of metanephric adenofibroma and related lesions: clinicopathologic study of 25 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol. 2001;25:433–44.

pubmed: 11257617 doi: 10.1097/00000478-200104000-00002

Mangray S, Breese V, Jackson CL, Lombardo K, Taliano R, Resnick M, et al. Application of BRAF V600E mutation analysis for the diagnosis of metanephric adenofibroma. Am J Surg Pathol. 2015;39:1301–4.

pubmed: 26274032 doi: 10.1097/PAS.0000000000000501

Chami R, Yin M, Marrano P, Teerapakpinyo C, Shuangshoti S, Thorner PS. BRAF mutations in pediatric metanephric tumors. Hum Pathol. 2015;46:1153–61.

pubmed: 26014474 doi: 10.1016/j.humpath.2015.03.019

Argani P, Lee J, Netto GJ, Zheng G, Tseh-Lin M, Park BH. Frequent BRAF V600E mutations in metanephric stromal tumor. Am J Surg Pathol. 2016;40:719–22.

pubmed: 26796506 doi: 10.1097/PAS.0000000000000603

Marsden L, Jennings LJ, Gadd S, Yu M, Perlman EJ, Cajaiba MM. BRAF exon 15 mutations in pediatric renal stromal tumors: prevalence in metanephric stromal tumors. Hum Pathol. 2017;60:32–6.

pubmed: 27769870 doi: 10.1016/j.humpath.2016.09.025

Pinto A, Signoretti S, Hirsch MS, Barletta JA. Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma. Histopathology. 2015;66:901–4.

pubmed: 25130952 doi: 10.1111/his.12509

Udager AM, Pan J, Magers MJ, Palapattu GS, Morgan TM, Montgomery JS, et al. Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma. Am J Surg Pathol. 2015;39:549–57.

pubmed: 25602792 pmcid: 4359621 doi: 10.1097/PAS.0000000000000377

Gupta S, Cheville JC, Galeano BK, Sukov WR, Herrera-Hernandez L, Reed KA, et al. Renal neoplasia with papillary architecture involving the pelvicalyceal system. Hum Pathol. 2020;107:46–57.

pubmed: 33166576 doi: 10.1016/j.humpath.2020.10.013

Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, et al. BRAF mutations in metanephric adenoma of the kidney. Eur Urol. 2012;62:917–22.

pubmed: 22727996 pmcid: 4516083 doi: 10.1016/j.eururo.2012.05.051

Calio A, Eble JN, Hes O, Martignoni G, Harari SE, Williamson SR, et al. Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. Oncotarget. 2017;8:54096–105.

pubmed: 28903326 doi: 10.18632/oncotarget.11117

Wobker SE, Matoso A, Pratilas CA, Mangray S, Zheng G, Lin MT, et al. Metanephric adenoma-epithelial wilms tumor overlap lesions: an analysis of BRAF status. Am J Surg Pathol. 2019;43:1157–69.

pubmed: 31192863 doi: 10.1097/PAS.0000000000001240

Obasaju P, Shahab S, Dunn E, Rhee DS, Jiang L, Dome JS, et al. BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition. Cold Spring Harb Mol Case Stud. 2020;6:e004820.

de Vries-Brilland M, Sionneau B, Dutriaux C, Blay JY, Ravaud A, Gross-Goupil M. Successful treatment of metastatic adult wilms tumor with anti-BRAF treatment: a case report and a brief review of the literature. Clin Genitourin Cancer. 2019;17:e721–3.

pubmed: 31109800 doi: 10.1016/j.clgc.2019.02.012

Chan E, Stohr BA, Croom NA, Cho SJ, Garg K, Troxell ML, et al. Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution. Histopathology. 2020;76:1084–90.

pubmed: 32064677 doi: 10.1111/his.14094

Ding Y, Wang C, Li X, Jiang Y, Mei P, Huang W, et al. Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases. Diagn Pathol. 2018;13:54.

pubmed: 30111351 pmcid: 6094885 doi: 10.1186/s13000-018-0732-x

Kuroda N, Trpkov K, Gao Y, Tretiakova M, Liu YJ, Ulamec M, et al. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod Pathol. 2020;33:2564–79.

Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol. 2014;32:431–7.

pubmed: 24378414 doi: 10.1200/JCO.2013.50.8192

Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277–85.

pubmed: 20448661 pmcid: 2929006 doi: 10.1038/nrurol.2010.47

Gudbjartsson T, Jonasdottir TJ, Thoroddsen A, Einarsson GV, Jonsdottir GM, Kristjansson K, et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer. 2002;100:476–9.

pubmed: 12115533 doi: 10.1002/ijc.10513

Carlo MI, Hakimi AA, Stewart GD, Bratslavsky G, Brugarolas J, Chen YB, et al. Familial kidney cancer: implications of new syndromes and molecular insights. Eur Urol. 2019;76:754–64.

pubmed: 31326218 pmcid: 7673107 doi: 10.1016/j.eururo.2019.06.015

Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group, A. C. o. M. G. et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17:70–87.

pubmed: 25394175 doi: 10.1038/gim.2014.147

EVIQ. https://www.eviq.org.au/cancer-genetics/referral-guidelines/1146-referral-guidelines-for-kidney-cancer-risk-as . 2020.

Menko FH, Maher ER, Schmidt LS, Middelton LA, Aittomaki K, Tomlinson I, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014;13:637–44.

pubmed: 25012257 pmcid: 4574691 doi: 10.1007/s10689-014-9735-2

Harrison WJ, Andrici J, Maclean F, Madadi-Ghahan R, Farzin M, Sioson L, et al. Fumarate hydratase-deficient uterine leiomyomas occur in both the syndromic and sporadic settings. Am J Surg Pathol. 2016;40:599–607.

pubmed: 26574848 pmcid: 4830748 doi: 10.1097/PAS.0000000000000573

Turchini J, Cheung VKY, Tischler AS, De Krijger RR, Gill AJ. Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology. 2018;72:97–105.

pubmed: 29239044 doi: 10.1111/his.13402

Lau HD, Chan E, Fan AC, Kunder CA, Williamson SR, Zhou M, et al. A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol. 2020;44:98–110.

pubmed: 31524643 doi: 10.1097/PAS.0000000000001372

Martinek P, Grossmann P, Hes O, Bouda J, Eret V, Frizzell N, et al. Genetic testing of leiomyoma tissue in women younger than 30 years old might provide an effective screening approach for the hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC). Virchows Arch. 2015;467:185–91.

pubmed: 25985877 doi: 10.1007/s00428-015-1783-y

Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31:1578–85.

pubmed: 17895761 doi: 10.1097/PAS.0b013e31804375b8

Muller M, Ferlicot S, Guillaud-Bataille M, Le Teuff G, Genestie C, Deveaux S, et al. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers. Clin Genet. 2017;92:606–15.

pubmed: 28300276 doi: 10.1111/cge.13014

Smith SC, Sirohi D, Ohe C, McHugh JB, Hornick JL, Kalariya J, et al. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma. Histopathology. 2017;71:42–52.

pubmed: 28165631 doi: 10.1111/his.13183

Li Y, Reuter VE, Matoso A, Netto GJ, Epstein JI, Argani P. Re-evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients. Histopathology. 2018;72:588–600.

pubmed: 28898443 doi: 10.1111/his.13395

Gupta S, Swanson AA, Chen YB, Lopez T, Milosevic D, Kipp BR, et al. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Hum Pathol. 2019;91:114–22.

Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology. 2012;44:285–92.

pubmed: 22544211 doi: 10.1097/PAT.0b013e3283539932

Gill AJ. Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology. 2018;72:106–16.

pubmed: 29239034 doi: 10.1111/his.13277

Gill AJ, Toon CW, Clarkson A, Sioson L, Chou A, Winship I, et al. Succinate dehydrogenase deficiency is rare in pituitary adenomas. Am J Surg Pathol. 2014;38:560–6.

pubmed: 24625421 pmcid: 3966922 doi: 10.1097/PAS.0000000000000149

Gill AJ, Chou A, Vilain R, Clarkson A, Lui M, Jin R, et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol. 2010;34:636–44.

pubmed: 20305538 doi: 10.1097/PAS.0b013e3181d6150d

Turchini J, Gill AJ. Morphologic clues to succinate dehydrogenase (SDH) deficiency in pheochromocytomas and paragangliomas. Am J Surg Pathol. 2020;44:422–4.

pubmed: 31789631 doi: 10.1097/PAS.0000000000001415

Gill AJ, Pachter NS, Chou A, Young B, Clarkson A, Tucker KM, et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol. 2011;35:1578–85.

pubmed: 21934479 doi: 10.1097/PAS.0b013e318227e7f4

Gill AJ, Hes O, Papathomas T, Sedivcova M, Tan PH, Agaimy A, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38:1588–602.

pubmed: 25025441 pmcid: 4229399 doi: 10.1097/PAS.0000000000000292

Williamson SR, Eble JN, Amin MB, Gupta NS, Smith SC, Sholl LM, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol. 2015;28:80–94.

pubmed: 25034258 doi: 10.1038/modpathol.2014.86

Gill AJ, Lipton L, Taylor J, Benn DE, Richardson AL, Frydenberg M, et al. Germline SDHC mutation presenting as recurrent SDH deficient GIST and renal carcinoma. Pathology. 2013;45:689–91.

pubmed: 24150194 doi: 10.1097/PAT.0000000000000018

Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96:E1472–6.

pubmed: 21752896 doi: 10.1210/jc.2011-1043

Yakirevich E, Ali SM, Mega A, McMahon C, Brodsky AS, Ross JS, et al. A novel SDHA-deficient renal cell carcinoma revealed by comprehensive genomic profiling. Am J Surg Pathol. 2015;39:858–63.

pubmed: 25724004 doi: 10.1097/PAS.0000000000000403

Ozluk Y, Taheri D, Matoso A, Sanli O, Berker NK, Yakirevich E, et al. Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. Hum Pathol. 2015;46:1951–5.

pubmed: 26476567 doi: 10.1016/j.humpath.2015.07.027

Jiang Q, Zhang Y, Zhou YH, Hou YY, Wang JY, Li JL, et al. A novel germline mutation in SDHA identified in a rare case of gastrointestinal stromal tumor complicated with renal cell carcinoma. Int J Clin Exp Pathol. 2015;8:12188–97.

pubmed: 26722403 pmcid: 4680348

McEvoy CR, Koe L, Choong DY, Leong HS, Xu H, Karikios D, et al. SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response. NPJ Precis Oncol. 2018;2:9.

pubmed: 29872718 pmcid: 5871886 doi: 10.1038/s41698-018-0053-2

Benn DE, Zhu Y, Andrews KA, Wilding M, Duncan EL, Dwight T, et al. Bayesian approach to determining penetrance of pathogenic SDH variants. J Med Genet. 2018;55:729–34.

pubmed: 30201732 doi: 10.1136/jmedgenet-2018-105427

Dwight T, Benn DE, Clarkson A, Vilain R, Lipton L, Robinson BG, et al. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol. 2013;37:226–33.

pubmed: 23060355 doi: 10.1097/PAS.0b013e3182671155

Schmidt LS, Linehan WM. Molecular genetics and clinical features of Birt-Hogg-Dube syndrome. Nat Rev Urol. 2015;12:558–69.

pubmed: 26334087 pmcid: 5119524 doi: 10.1038/nrurol.2015.206

Iwabuchi C, Ebana H, Ishiko A, Negishi A, Mizobuchi T, Kumasaka T, et al. Skin lesions of Birt-Hogg-Dube syndrome: Clinical and histopathological findings in 31 Japanese patients who presented with pneumothorax and/or multiple lung cysts. J Dermatol Sci. 2018;89:77–84.

pubmed: 29157599 doi: 10.1016/j.jdermsci.2017.10.014

Furuya M, Nakatani Y. Birt-Hogg-Dube syndrome: clinicopathological features of the lung. J Clin Pathol. 2013;66:178–86.

pubmed: 23223565 doi: 10.1136/jclinpath-2012-201200

Furuya M, Yao M, Tanaka R, Nagashima Y, Kuroda N, Hasumi H, et al. Genetic, epidemiologic and clinicopathologic studies of Japanese Asian patients with Birt-Hogg-Dube syndrome. Clin Genet. 2016;90:403–12.

pubmed: 27220747 doi: 10.1111/cge.12807

Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol. 2002;26:1542–52.

pubmed: 12459621 doi: 10.1097/00000478-200212000-00002

Furuya M, Hasumi H, Yao M, Nagashima Y. Birt-Hogg-Dube syndrome-associated renal cell carcinoma: Histopathological features and diagnostic conundrum. Cancer Sci. 2020;111:15–22.

pubmed: 31777168 doi: 10.1111/cas.14255

Iribe Y, Yao M, Tanaka R, Kuroda N, Nagashima Y, Nakatani Y, et al. Genome-wide uniparental disomy and copy number variations in renal cell carcinomas associated with Birt-Hogg-Dube syndrome. Am J Pathol. 2016;186:337–46.

pubmed: 26776076 doi: 10.1016/j.ajpath.2015.10.013

Lang M, Vocke CD, Merino MJ, Schmidt LS, Linehan WM. Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt-Hogg-Dube tumors. Mod Pathol. 2015;28:1458–69.

pubmed: 26428318 pmcid: 4628590 doi: 10.1038/modpathol.2015.101

Falzarano SM, McKenney JK, Montironi R, Eble JN, Osunkoya AO, Guo J, et al. Renal cell carcinoma occurring in patients with prior neuroblastoma: a heterogenous group of neoplasms. Am J Surg Pathol. 2016;40:989–97.

pubmed: 26975037 doi: 10.1097/PAS.0000000000000632

Gupta S, Vanderbilt CM, Leibovich BC, Herrera-Hernandez L, Raghunathan A, Sukov WR, et al. Secondary renal neoplasia following chemotherapy or radiation in pediatric patients. Hum Pathol. 2020;103:1–13.

pubmed: 32681944 pmcid: 8935764 doi: 10.1016/j.humpath.2020.07.014

Argani P, Lae M, Ballard ET, Amin M, Manivel C, Hutchinson B, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol. 2006;24:1529–34.

pubmed: 16575003 doi: 10.1200/JCO.2005.04.4693

Wilson CL, Ness KK, Neglia JP, Hammond S, Shnorhavorian M, Leisenring WL, et al. Renal carcinoma after childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2013;105:504–8.

pubmed: 23515901 pmcid: 3691945 doi: 10.1093/jnci/djt014

Schimke RN, Collins DL, Stolle CA. Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery. Am J Med Genet A. 2010;152A:1531–5.

pubmed: 20503330

Curry S, Ibrahim F, Grehan D, McDermott M, Capra M, Betts D, et al. Rhabdomyosarcoma-associated renal cell carcinoma: a link with constitutional Tp53 mutation. Pediatr Dev Pathol. 2011;14:248–51.

pubmed: 21054160 doi: 10.2350/10-07-0871-CR.1

Trpkov K, Hes O, Bonert M, Lopez JI, Bonsib SM, Nesi G, et al. Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016;40:60–71.

pubmed: 26414221 doi: 10.1097/PAS.0000000000000508

Trpkov K, Abou-Ouf H, Hes O, Lopez JI, Nesi G, Comperat E, et al. Eosinophilic solid and cystic renal cell carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity. Am J Surg Pathol. 2017;41:1299–308.

pubmed: 28786877 doi: 10.1097/PAS.0000000000000838

Kuroda N, Karashima T, Inoue K, Kasajima A, Ohe C, Kawakami F, et al. Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects. Pol J Pathol. 2015;66:3–8.

pubmed: 26017874 doi: 10.5114/pjp.2015.51147

Kim H, Inomoto C, Uchida T, Kajiwara H, Komiyama T, Kobayashi H, et al. Impact of rhabdoid differentiation on postoperative outcome for patients with N0M0 renal cell carcinoma. Urol Oncol. 2019;37:711–20.

pubmed: 31174957 doi: 10.1016/j.urolonc.2019.05.012

Yang B, Xia H, Xu C, Lu M, Zhang S, Wang G, et al. Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically. BMC Urol. 2020;20:14.

pubmed: 32070319 pmcid: 7029456 doi: 10.1186/s12894-020-0584-z

Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boorjian SA, Cheville JC, et al. A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int. 2015;115:405–11.

pubmed: 24730416 doi: 10.1111/bju.12781

Perrino CM, Hucthagowder V, Evenson M, Kulkarni S, Humphrey PA. Genetic alterations in renal cell carcinoma with rhabdoid differentiation. Hum Pathol. 2015;46:9–16.

pubmed: 25439741 doi: 10.1016/j.humpath.2014.09.001

Kinoshita F, Kohashi K, Sugimoto M, Takamatsu D, Kiyozawa D, Eto M, et al. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features. Virchows Arch. 2020. https://doi.org/10.1007/s00428-020-02839-z .

Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, et al. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015;28:1225–35.

pubmed: 26111976 pmcid: 4556533 doi: 10.1038/modpathol.2015.68

Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, et al. Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape. Clin Cancer Res. 2017;23:6686–96.

pubmed: 28710314 pmcid: 5683086 doi: 10.1158/1078-0432.CCR-17-1057

Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, et al. Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations. Eur Urol. 2016;70:348–57.

pubmed: 26895810 doi: 10.1016/j.eururo.2016.01.051

Malouf GG, Flippot R, Dong Y, Dinatale RG, Chen YB, Su X, et al. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Sci Rep. 2020;10:701.

pubmed: 31959902 pmcid: 6971072 doi: 10.1038/s41598-020-57534-5

Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, et al. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw. 2019;17:1278–85.

pubmed: 31693980 doi: 10.6004/jnccn.2019.0054

Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020;17:137–50.

pubmed: 32020040 doi: 10.1038/s41585-020-0282-3

Motzer RJ, Escudier B, McDermott DF, Aren Frontera O, Melichar B, Powles T, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020;8;e000891.

Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, et al. PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer Immunol Res. 2015;3:1303–7.

pubmed: 26307625 pmcid: 4674298 doi: 10.1158/2326-6066.CIR-15-0150

Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, et al. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017;123:4823–31.

pubmed: 28832979 doi: 10.1002/cncr.30937

Gupta S, Cheville JC, Jungbluth AA, Zhang Y, Zhang L, Chen YB, et al. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Mod Pathol. 2019;32:1344–58.

pubmed: 30996253 pmcid: 7189735 doi: 10.1038/s41379-019-0269-x

Kiyozawa D, Takamatsu D, Kohashi K, Kinoshita F, Ishihara S, Toda Y, et al. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features. Hum Pathol. 2020;101:31–9.

pubmed: 32360490 doi: 10.1016/j.humpath.2020.04.003

Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2021:27:78–86.

New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Références

Auteurs

Articles similaires

Classifications MeSH